~~<i id='63029978E3'><strike id='63029978E3'><tt id='63029978E3'><pre id='63029978E3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

fashion

author：Wikipedia 2025-09-30 00:37:05 - browse：899

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： BMI, flaws aside, is found to be useful estimate of body fat in youth

entertainment

hotspot

explore

Wikipedia

KristineChuaIllustration:STAT;Courtesy:KristineChuaChimeras—fantasticalcreaturescomposedofdifferenta

WSS

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Bill would allow buprenorphine prescription for addiction via telehealth

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

The health care issue Democrats can’t solve: hospital reform

Medicare proceeds with plan to claw back hospital funds

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

hotspot

fashion

entertainment

Peter Hotez and the public health issue of online harassment

Let's speed up science by embracing open access publishing

Wildfire smoke exposes gaps in outdoor worker protections

Travis Kelce and the trap of celebrity vaccine endorsements

Medical records are filled with copy

Medicare must police algorithms in Medicare Advantage, Dems say

In Memoriam: Notable people who died in 2023

Lung cancer screening guidelines updated for cigarette smokers

ChatGPT in medicine: STAT answers readers' burning questions

Letters to First Opinion on caregivers, digital health, and more

hotspot

Humans aren't the only ones with an imagination. Rats have it too

Gene therapy’s promise and the high cost of hope

Travis Kelce and the trap of celebrity vaccine endorsements

With trial win, GSK could get blood cancer drug back on market

Kidney transplant patients stopped immunosuppressants in trial

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

explore

explore

explore

Wikipedia